“The present problem has uncovered some structural weaknesses while in the EU’s medicines provide chain in addition to a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides claimed. She advised that provide chain problems be resolved within an EU pharmaceutical approach expected to generally be launch